The role of the new β-blockers in treating cardiovascular disease

American Journal of Hypertension

Volumn 18, Issue 12 SUPPL., 2005, Pages 169-176

  Weber, Michael A ^a,b  

^a STATE UNIVERSITY OF NEW YORK   (United States)

^b SUNY Downstate Medical Center   (United States)

Author keywords

Cardiovascular disease; Hypertension; Nebivolol; blocker

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METOPROLOL; NEBIVOLOL; PLACEBO; TRIACYLGLYCEROL;

BETA ADRENERGIC RECEPTOR BLOCKING; BRADYCARDIA; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CONFERENCE PAPER; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG EFFICACY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; EDEMA; ESSENTIAL HYPERTENSION; FATIGUE; HEADACHE; HEART LEFT VENTRICLE FUNCTION; HUMAN; INSULIN SENSITIVITY; INTRINSIC SYMPATHOMIMETIC ACTIVITY; PRIORITY JOURNAL; SEXUAL DYSFUNCTION; STRUCTURE ACTIVITY RELATION; SYMPATHETIC TONE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 29144495544     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2005.09.009     Document Type: Conference Paper

References (67)

1. J. López-Sendón, K. Swedberg, J. McMurray, J. Tamargo, A.P. Maggioni, H. Dargie, M. Tendera, F. Waagstein, J. Kjekshus, P. Lechat, C. Torp-Pedersen Task Force on Beta-Blockers of the European Society of Cardiology Expert consensus document on β-adrenergic receptor blockers Eur Heart J 25 2004 1341 1362
2. A.V. Chobanian, G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, J.L. Izzo Jr, D.W. Jones, B.J. Materson, S. Oparil, J.T. Wright Jr, E.J. Roccella National High Blood Pressure Education Program Coordinating Committee The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure the JNC 7 report JAMA 289 2003 2560 2572
3. P.A. Ubel, C. Jepson, D.A. Asch Misperceptions about β-blockers and diuretics a national survey of primary care physicians J Gen Intern Med 18 2003 977 983
4. K.E. Ellison, G. Gandhi Optimising the use of beta-adrenoreceptor antagonists in coronary artery disease Drugs 65 2005 787 797
5. J.B. Soriano, A.W. Hoes, L. Meems, D.E. Grobbee Increased survival with beta-blockers importance of ancillary properties Prog Cardiovasc Dis 39 1997 445 456
6. N. Freemantle, J. Cleland, P. Young, J. Mason, J. Harrison β Blockade after myocardial infarction systematic review and meta regression analysis BMJ 318 1999 1730 1737
7. M.R. Bristow β-Adrenergic receptor blockade in chronic heart failure Circulation 101 2000 558 569
8. 1αAR splice variants J Biol Chem 277 2002 9570 9579
9. M.R. Bristow, A.M. Feldman, K.F. Adams Jr, S. Goldstein Selective versus nonselective β-blockade for heart failure therapy are there lessons to be learned from the COMET trial? J Card Fail 9 2003 444 453
10. K. Brixius, A. Bundkirchen, R. Bolck, U. Mehlhorn, R.H. Schwinger Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium Br J Pharmacol 133 2001 1330 1338
11. D.G. McDevitt Pharmacologic aspects of cardioselectivity in a beta-blocking drug Am J Cardiol 59 1987 10F 12F
12. A.J. Bowman, C.P. Chen, G.A. Ford Nitric oxide mediated venodilator effects of nebivolol Br J Clin Pharmacol 38 1994 199 204
13. J.R. Cockcroft, P.J. Chowienczyk, S.E. Brett, C.P.L. Chen, A.G. Dupont, L. Van Nueten, S.J. Wooding, J.M. Ritter Nebivolol vasodilates human forearm vasculature evidence for L-arginine/NO-dependent mechanism J Pharmacol Exp Ther 274 1995 1067 1071
14. M. Dawes, S.E. Brett, P.J. Chowienczyk, T.G.K. Mant, J.M. Ritter The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension Br J Clin Pharmacol 48 1999 460 463
15. N. Tzemos, P.O. Lim, T.M. MacDonald Nebivolol reverses endothelial dysfunction in essential hypertension a randomized, double-blind, crossover study Circulation 104 2001 511 514
16. J.M. Ritter Nebivolol endothelium-mediated vasodilating effect J Cardiovasc Pharmacol 38 Suppl 3 2001 S13 S16
17. P. Jaillon Relevance of intrinsic sympathomimetic activity for beta blockers Am J Cardiol 66 1990 21C 23C
18. B.N.C. Prichard Pharmacologic aspects of intrinsic sympathomimetic activity in beta-blocking drugs Am J Cardiol 59 1987 13F 17F
19. B.M. Psaty, N.L. Smith, D.S. Siscovick, T.D. Koepsell, N.S. Weiss, S.R. Heckbert, R.N. Lemaitre, E.H. Wagner, C.D. Furberg Health outcomes associated with antihypertensive therapies used as first-line agents a systematic review and meta-analysis JAMA 277 1997 739 745
20. S.S. Gottlieb, R.J. McCarter Comparative effects of three beta blockers (atenolol, metoprolol, and propranolol) on survival after acute myocardial infarction Am J Cardiol 87 2001 823 826
21. S.A. Hunt, D.W. Baker, M.H. Chin, M.P. Cinquegrani, A.M. Feldman, G.S. Francis, T.G. Ganiats, S. Goldstein, G. Gregoratos, M.L. Jessup, J. Noble, M. Packer, M.A. Silver, L.W. Stevenson American College of Cardiology/American Heart Association ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure) J Am Coll Cardiol 38 2001 2101 2113
22. J.M. Foody, M.H. Farrell, H.M. Krumholz β-Blocker therapy in heart failure scientific review JAMA 287 2002 883 889
23. CIBIS II Investigators and Committees The Cardiac Insufficiency Bisoprolol Study (CIBIS II) a randomised trial Lancet 353 1999 9 13
24. MERIT-HF Study Group Effect of metoprolol CR/XL in chronic heart failure Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet 353 1999 2001 2007
25. M. Packer, M.R. Bristow, J.N. Cohn, W.S. Colucci, M.B. Fowler, E.M. Gilbert, N.H. Shusterman U.S. Carvedilol Heart Failure Study Group The effect of carvedilol on morbidity and mortality in patients with chronic heart failure N Engl J Med 334 1996 1349 1355
26. M. Packer, A.J. Coats, M.B. Fowler, H.A. Katus, H. Krum, P. Mohacsi, J.L. Rouleau, M. Tendera, A. Castaigne, E.B. Roecker, M.K. Schultz, D.L. DeMets Carvedilol Prospective Randomized Cumulative Survival Study Group Effect of carvedilol on survival in severe chronic heart failure N Engl J Med 344 2001 1651 1658
27. B.N. Prichard Beta-adrenergic blocking drugs in the treatment of hypertension Blood Press 10 2001 366 386
28. T.W. Gress, F.J. Nieto, E. Shahar, M.R. Wofford, F.L. Brancati Atherosclerosis Risk in Communities Study Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus N Engl J Med 342 2000 905 912
29. S. Jacob, K. Rett, E.J. Henriksen Antihypertensive therapy and insulin sensitivity do we have to redefine the role of β-blocking agents? Am J Hypertens 11 1998 1258 1265
30. J.M. Cruickshank Beta-blockers and diabetes the bad guys come good Cardiovasc Drugs Ther 16 2002 457 470
31. UK Prospective Diabetes Study Group Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes UKPDS 39 BMJ 317 1998 713 720
32. S.J. Haas, T. Vos, R.E. Gilbert, H. Krum Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials Am Heart J 146 2003 848 853
33. D. Giugliano, R. Acampora, R. Marfella, N. De Rosa, P. Ziccardi, R. Ragone, L. De Angelis, F. D'Onofrio Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension Ann Intern Med 126 1997 955 959
34. W.H. Frishman Clinical significance of beta 1-selectivity and intrinsic sympathomimetic activity in a beta-adrenergic blocking drug Am J Cardiol 59 1987 33F 37F
35. S. Jacob, E.J. Henriksen Metabolic properties of vasodilating β blockers management considerations for hypertensive diabetic patients and patients with the metabolic syndrome J Clin Hypertens 6 2004 690 698
36. G.L. Bakris, V. Fonseca, R.E. Katholi, J.B. McGill, F.H. Messerli, R.A. Phillips, J.T. Wright, R. Oakes, M.M. Lukas, K.M. Anderson, D.S.H. Bell GEMINI Investigators Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension. A randomized controlled trial JAMA 292 2004 2227 2236
37. M. Mangrella, F. Rossi, F. Fici, F. Rossi Pharmacology of nebivolol Pharmacol Res 38 1998 419 431
38. 1- adrenoreceptor antagonist, nebivolol Cardiovasc Drug Rev 22 2004 155 168
39. A. Van Peer, E. Snoeck, R. Woestenborghs, V. Van de Velde, G. Mannens, W. Meuldermans, J. Heykants Clinical pharmacokinetics of nebivolol a review Drug Invest 3 Suppl 1 1991 25 30
40. W. McNeely, K.L. Goa Nebivolol in the management of essential hypertension a review Drugs 57 1999 633 651
41. 1-adrenergic receptor selectivity of nebivolol and various other beta-blockers in human myocardium [abstract] Am J Hypertens 18 2005 51A 52A Abstract P-121
42. 1- adrenergic antagonist J Cardiovasc Pharmacol 11 1988 552 563
43. A. Himmelman, T. Hedner, E. Snoeck, B. Lundgren, J. Hedner Haemodynamic effects and pharmacokinetics of oral d- and l-nebivolol in hypertensive patients Eur J Clin Pharmacol 51 1996 259 264
44. J. De Cree, C. Cobo, H. Geukens, H. Verhaegen Comparison of the subacute hemodynamic effects of atenolol, propranolol, pindolol, and nebivolol Angiology 41 1990 95 105
45. J. De Cree, L. Van Nueten, H. Geukens, H. Verhaegen Comparative cardiac haemodynamics of bisoprolol, celiprolol, carvedilol and nebivolol in normal volunteers Int J Clin Pharmacol Res 12 1992 159 163
46. M.F. Rousseau, F. Chapelle, C. Van Eyll, L. Stoleru, D. Hager, L. Van Nueten, H. Pouleur Medium-term effects of beta-blockade on left ventricular mechanics a double-blind, placebo-controlled comparison of nebivolol and atenolol in patients with ischemic left ventricular dysfunction J Card Fail 2 1996 15 23
47. L. Stoleru, W. Wijns, C. Van Eyll, T. Bouvy, L. Van Nueten, H. Pouleur Effects of D-nebivolol and L-nebivolol on left ventricular systolic and diastolic function comparison with D-L nebivolol and atenolol J Cardiovasc Pharmacol 22 1993 183 190
48. M. Goldstein, J.L. Vincent, J.M. De Smet, L. Barvais, L. Van Nueten, H. Scheijgrond, A. d'Hollander, J.L. Leclerc, R. Kahm Administration of nebivolol after coronary artery bypass in patients with altered left ventricular function J Cardiovasc Pharmacol 22 1993 253 258
49. O. Kamp, G.T. Sieswarda, C.A. Visser Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension Am J Cardiol 92 2003 344 348
50. S. Nodari, M. Metra, L. Dei Cas β-Blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized comparison of the long-term effects of atenolol vs. nebivolol Eur J Heart Fail 5 2003 621 627
51. C.M. McEniery, M. Schmitt, A. Qasem, D.J. Webb, A.P. Avolio, I.B. Wilkinson, J.R. Cockcroft Nebivolol increases arterial distensibility in vivo Hypertension 44 2004 305 310
52. M. Galderisi, S. Cicala, A. D'Errico, O. de Divitiis, G. de Simone Nebivolol improves coronary flow reserve in hypertensive patients without coronary heart disease J Hypertens 22 2004 2201 2208
53. L. Van Nueten, A.G. Dupont, C. Vertommen, H. Goyvaerts, J.I. Robertson A dose-response trial of nebivolol in essential hypertension J Hum Hypertens 11 1997 139 144
54. J.V. Fallois, H.-D. Faulhaber Nebivolol, a beta-blocker of the third generation: the current treatment of arterial hypertension: results of a multicenter observational study Praxis 90 2001 435 441
55. L. Van Nueten, F.R. Taylor, J.I.S. Robertson Nebivolol vs atenolol and placebo in essential hypertension a double-blind randomised trial J Hum Hypertens 12 1998 135 140
56. G. Grassi, F.Q. Trevano, A. Facchini, T. Toutouzas, B. Chanu, G. Mancia Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension results of a double-blind randomized multicentre trial Blood Press Suppl 2 2003 35 40
57. O. Uhlíř, M. Fejfuša, K. Havránek, K. Lefflerová, J. Vojáček, J. Widimský, J. Winterová, K. Zeman Nebivolol versus metoprolol in the treatment of hypertension Drug Invest 3 Suppl 1 1991 107 110
58. L. Van Nueten, A. Schelling, C. Vertommen, A.G. Dupont, J.I. Robertson Nebivolol vs enalapril in the treatment of essential hypertension a double-blind, randomised trial J Hum Hypertens 11 1997 813 819
59. Y. Lacourciére, J. Lefebvre, L. Poirier, F. Archamault, W. Arnott A double-blind crossover comparison of nebivolol and lisinopril in the treatment of ambulatory hypertension Am J Ther 1 1994 74 80
60. E.A. Rosei, D. Rizzoni, S. Comini, G. Boari Nebivolol-Lisinopril Study Group Evaluation of the efficacy and tolerability of nebivolol versus lisinopril in the treatment of essential arterial hypertension a randomized, multicentre, double-blind study Blood Press 12 Suppl 1 2003 30 35
61. L. Van Bortel, W. Mäkel, F. Fici Effect on office blood pressure differs between nebivolol and losartan when used at advocated daily doses [abstract] J Hypertens 21 Suppl 4 2003 S180 Abstract P2. 206
62. L. Van Bortel, W. Mäkel, F. Fici Quality of life does not differ between nebivolol and losartan [abstract] J Hypertens 21 Suppl 4 2003 S182 Abstract P2. 212
63. L. Van Nueten, Y. Lacourciére, G. Vyssoulis, K. Korlipara, D.M. Marcadet, A.G. Dupont, J.I.S. Robertson Nebivolol versus nifedipine in the treatment of essential hypertension a double-blind, randomized, comparative trial Am J Ther 5 1998 237 243
64. A. Mazza, B. Gil-Extremera, A. Maldonato, T. Toutouzas, A.C. Pessina Nebivolol vs amlodipine as first-line treatment of essential arterial hypertension in the elderly Blood Press 11 2002 182 188
65. M.D. Flather, M.C. Shibata, A.J.S. Coats, D.J. Van Veldhuisen, A. Parkhomenko, J. Borbola, A. Cohen-Solal, D. Dumitrascu, R. Ferrari, P. Lechat, J. Soler-Soler, L. Tavazzi, L. Spinarova, J. Toman, M. Böhm, S. Anker, S.G. Thompson, P.A. Poole-Wilson SENIORS Investigators Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS) Eur Heart J 26 2005 215 225
66. D.W. Kitzman, J.M. Gardin, J.S. Gottdiener, A. Arnold, R. Boineau, G. Aurigemma, E.K. Marino, M. Lyles, M. Cushman, P.L. Enright Cardiovascular Health Study Research Group Importance of heart failure with preserved systolic function in patients > or = 65 years of age Am J Cardiol 87 2001 413 419
67. E. Lichstein, W.D. Hager, J.J. Gregory, J.L. Fleiss, L.M. Rolnitzky, J.T. Bigger Jr Multicenter Diltiazem Post-Infarction Research Group Relation between beta-adrenergic blocker use, various correlates of left ventricular function and the chance of developing congestive heart failure J Am Coll Cardiol 16 1990 1327 1332